LGALS3 and heart failure: In fact, with regards to Gal-3 as a novel biomarker, the ACC/AHA guidelines recommended the use of Gal-3 for the assessment of cardiac fibrosis in heart failure; however, thus far, the ESC has not recommended the clinical use of Gal-3 [72].